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Abstract
N-linked glycosylation is one of the most frequent post-translational modifications of proteins with a profound impact on
their biological function. Besides other functions, N-linked glycosylation assists in protein folding, determines protein
orientation at the cell surface, or protects proteins from proteases. The N-linked glycans attach to asparagines in the
sequence context Asn-X-Ser/Thr, where X is any amino acid except proline. Any variation (e.g. non-synonymous single
nucleotide polymorphism or mutation) that abolishes the N-glycosylation sequence motif will lead to the loss of a
glycosylation site. On the other hand, variations causing a substitution that creates a new N-glycosylation sequence motif
can result in the gain of glycosylation. Although the general importance of glycosylation is well known and acknowledged,
the effect of variation on the actual glycoproteome of an organism is still mostly unknown. In this study, we focus on a
comprehensive analysis of non-synonymous single nucleotide variations (nsSNV) that lead to either loss or gain of the N-
glycosylation motif. We find that 1091 proteins have modified N-glycosylation sequons due to nsSNVs in the genome. Based
on analysis of proteins that have a solved 3D structure at the site of variation, we find that 48% of the variations that lead to
changes in glycosylation sites occur at the loop and bend regions of the proteins. Pathway and function enrichment analysis
show that a significant number of proteins that gained or lost the glycosylation motif are involved in kinase activity,
immune response, and blood coagulation. A structure-function analysis of a blood coagulation protein, antithrombin III and
a protease, cathepsin D, showcases how a comprehensive study followed by structural analysis can help better understand
the functional impact of the nsSNVs.
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Introduction
Protein glycosylation, one of the most common post transla-
tional modifications, involves enzymatic addition of oligosaccha-
rides, also referred to as glycans or carbohydrates, to proteins. The
oligosaccharides commonly found on a protein are either N-linked
or O-linked. N-linked glycans, the focus of this paper, are attached
to the –NH2 group of asparagines. N-glycosylation of proteins
strongly influences their function including folding, cellular
localization, and turnover [1–7]. A specific NX(S/T) amino acid
sequence motif is commonly required for N-glycosylation of
proteins. In this sequon, N is asparagine, S/T is either serine or
threonine, and X is any amino acid except proline [5]. Not all
NX(S/T) sequences in protein molecules are glycosylated because
some are not accessible to the glycosylation enzymes [8]. Other
sequence motifs for the attachment of N-glycans have been
described but are utilized with much lower frequency [9].
Although the general importance of N-glycosylation is acknowl-
edged, the actual N-glycoproteome of an organism is only
beginning to emerge [9]. Decoding the function of glycoproteins
in a comprehensive manner is one of the major challenges of the
post-genomic era. Because changes in the structure of N-glycans
attached to the glycoproteins are sufficient to cause disease,
research on N-glycosylation in the disease context is particularly
important [3]. Mutations in glycosyltransferases, leading to
truncated N-glycans, cause congenital disorders of glycosylation
[10]. More subtle examples include highly branched sialylated N-
glycoproteins that facilitate metastatic cancer diseases [2] [11].
The protein N-glycosylation signals are further amplified by an
entire glycan recognition network including galectins, siglecs and
other interacting partners which magnify their functional impact
[12]. The evidence for causality in such complex phenotypes may
be difficult to establish [13]. However, complex changes in the N-
glycan structures are not the only possible modification; direct
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proteins to diseases [14–18].
According to a recent study, 27 out of 31 mutations of the
NX(S/T) motif were found to be associated with genetic diseases
[19]. Mutations leading to the gain of glycosylation have been
associated with myoclonus-dystonia syndrome [20]; growth
retardation due to inhibited secretion of insulin-like growth
factor-binding protein [21]; and rolandic seizures [22]. Suscepti-
bility to mycobacterial infections was shown to be caused by the
T168N gain of N-glycosylation mutantation of IFNGR2 [14].
Kretz et al. showed that abolition of a glycosite in saposine B
results in accelerated proteolysis and metachromatic leukodystro-
phy. The authors identified several other human proteins affected
by the proximity of a proteolytic site to the N-glycosylation sequon
[23]. Because the N-glycosylation sites have been shown to be
protected and selection mechanisms that fix the N-glycosites in the
population have been suggested [24], it is plausible that SNVs
affecting N-glycosylation sites contribute significantly to human
diseases [25]. For example, the D327N variant of the sex
hormone-binding globulin (SHBG) which creates a new glycosyl-
ation site was shown to be protective in breast cancer [26,27]. It
was suggested that distribution of SHBG between circulation and
tissues is affected by the N-glycosylation status at the D327N
polymorphic site [28]. This underscores the need for further
research on the impact of the N-glyco variants on protein function
and human diseases.
Our goal is to build a framework for better understanding the
effects of non-synonymous single nucleotide variations (nsSNV) on
the N-glycosylation of proteins. We focus on a comprehensive
analysis of the non-synonymous (missense) substitutions that lead
to either loss or gain of the N-glycosylation motif. As described
above, there are examples of the impact of individual polymorphic
sites but, surprisingly, a comprehensive survey of the impact of
SNV on the N-glycosylation sequon has not been presented to the
best of our knowledge. To assess the overall impact of the nsSNV
on the human proteome, we have extracted the N-glycosylation
and variation data from the UniProtKB/Swiss-Prot [29] and
dbSNP data from PolyPhen [30]. The survey is followed by
evaluation of functional enrichment within our dataset with
specific examples of protein structure-function analysis. We expect
that this compact information and novel use of proteome-wide
data will provide researchers with improved tools for the design of
innovative studies to understand the impact of nsSNV on human
diseases.
Materials and Methods
The complete human proteome was obtained from the
manually curated UniProtKB/Swiss-Prot (UniProt release
2011_01) [29]. The nsSNV variation data were extracted from
UniProtKB/Swiss-Prot and PolyPhen (accessed July 2010) [30]
which provides dbSNP data mapped to UniProtKB/Swiss-Prot.
Figure 1. Flow chart of the method used to identify polymorphic glycoproteins.
doi:10.1371/journal.pone.0036212.g001
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motif/s due to missense genomic variation were recorded for
further annotation and analysis. Information on pathways,
structure, Pfam domain and disease association was collected
from UniProtKB. All proteins that gained glycosylation sites were
evaluated using the N-glycosylation prediction tool NetNGlyc
[http://www.cbs.dtu.dk/services/NetNGlyc/]. Prediction of the
N-terminal targeting sequences for endoplasmic reticulum was
performed using Predotar [31].
Enrichment analysis was performed to identify over- or under-
represented Pfam domains in the loss and gain of glycosylation
dataset, compared to their occurrence in the entire human
proteome. The expected occurrence of a domain in the dataset
was calculated based on the actual number of times it is present in
the human proteome. A p value of 0.05 was considered significant
and was calculated based on methodology described earlier [32].
In order to understand the nature of variations in the protein
families, all the proteins in the data set were clustered using
iProClust [http://pir.georgetown.edu/cgi-bin/iProClust.pl]. This
process iteratively clusters the closely related proteins based on
their length and similarity. Pathways were analyzed using
Ingenuity Pathway AnalysisH (IPA) tools, a web based interface
for Ingenuity Knowledge Base (IngenuityH Systems, http://www.
ingenuity.com).
To calculate the representation of nsSNVs within the human
proteome or a dataset, the calculations were done in the following
manner: total number of nsSNVs in human proteome divided by
length of proteome (sum of the protein lengths); total number of
nsSNVs in dataset divided by the length of all the proteins in the
dataset. The p value was calculated based on methodology
described earlier [32].
PyMOL (www.pymol.org) was used to model the amino acid
variation and generate the structure figures. The accessible solvent
area was checked by ASAView [33]. The homology model was
built by using the SWISS_MODEL [http://swissmodel.expasy.
org/] and the structural comparison was done using FATCAT
[http://fatcat.ljcrf.edu/fatcat-cgi/cgi/fatcat.pl?-func=pairwise].
Results and Discussion
The human proteome available from UniProtKB/Swiss-Prot
contains curated information in the feature (FT) lines with regards
to experimentally characterized and predicted glycosylation sites
[29]. The database entries also provide information on nsSNV.
The dbSNP database at NCBI [34,35] also has information on
missense variations. A comparison of dbSNP with UniProtKB/
Swiss-Prot shows that, although there is some overlap, there is
variation data unique to just one of the databases. Therefore, a
comprehensive analysis of the impact of sequence polymorphism
on the loss/gain of protein glycosites requires merging of the
information from dbSNP and UniProt. In this study, we focus on
the analysis of non-synonymous substitutions that lead to either
loss or gain of the N-glycosylation motif. All the variations were
mapped for further analysis to the reference human proteome
available from UniProtKB/Swiss-Prot.
Impact of nsSNV on the NXS/T Motif
To identify proteins that lose the NXS/T glycosylation sequon
due to nsSNV, all the glycosylated proteins from the human
proteome were extracted from UniProtKB. A flowchart describ-
ing the process is presented in Figure 1 and a summary of these
findings is presented in Table 1 (the entire dataset is available in
Table S1). UniProtKB/Swiss-Prot annotates 4421 proteins (22%
of human proteins) with N- and O- linked glycosylation sites. Of
these, 3680 proteins (18% of the human proteome) have one or
more N-linked glycosylation sites. This is a fraction of the 15,313
proteins with NXS/T (where X is not a P) motifs in the human
proteome, however, there is evidence that only fraction a of the
Table 1. Summary of results of loss and gain of N-glycosylation in the human proteome.
Description Number
Human proteins annotated as N-glycosylated in UniProtKB/Swiss prot 3680
Confirmed N-linked glycoproteins 967
Proteins that have one or more glycosylation sites abolished due to nsSNV 226
Glycosylation sites lost due to nsSNV 259
Proteins that have one or more new glycosylation sites formed due to nsSNV 917
Glycosylation sites gained due to nsSNV 1091
Protein variants that have structural information at the N-glycosylation site (includes loss and gain sites) 279
doi:10.1371/journal.pone.0036212.t001
Table 2. Cellular component that the protein occupies as defined in UniProtKB/Swiss-Prot keyword
1.
Cellular component # of proteins in complete proteome
2 # of nsSNV carrying glycoproteins
3
Secreted 1814 178
Membrane 6714 477
Cytoplasm 3987 204
Nucleus 4690 218
1The same proteins can have more than one keyword if it is found to be present in more than one location.
215293 out of the total 20242 proteins in the human proteome have a Cellular Component keyword.
3935 out 1091 nsSNV glycoproteins have a Cellular Component keyword.
doi:10.1371/journal.pone.0036212.t002
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occupancy of N-glycosylation sites in human is at the moment
incomplete but the most complete annotation of glycosylated
proteins is likely the UniProtKB/Swiss-Prot database. For
identifying proteins that lose the glycosylation motif, we therefore
considered in our analysis the 3680 proteins annotated as N-
glycosylated by the UniProtKB/Swiss-Prot which is considered
the gold standard set of manually curated human proteins.
On mapping the variation data to the UniProtKB/Swiss-Prot
human proteome, we find that 259 unique variations resulted in
the loss of N-glycosylation in 226 proteins (6% of the proteins that
are N-glycosylated). A total of 28 proteins are predicted to contain
more than one NXS/T site lost due to the nsSNV (see Table 1 and
Table S2). Similarly, the proteins that gain the N-glycosylation
motif due to nsSNV were identified by mapping the variation data
from UniProtKB and PolyPhen to the UniProtKB/Swiss-Prot
human proteome. It was found that 1073 unique variations
resulted in gain of the N-glycosylation motif in 917 proteins (5% of
the human proteome). In total, 1091 proteins (loss plus gain) were
found to have variation at the N-glycosylation sequon. 113
proteins gained more than one NXS/T site due to the nsSNV (see
Table 1 and Table S2). Even though the likelihood of having two
nsSNVs affecting the protein in the same person is low, it is
important to note that the number of ways the protein can gain
new N-glycosylation site increases. The majority of the proteins in
our dataset gained a single new N-glycosylation site due to nsSNV;
some of the non-glycoproteins acquired one or more NXS/T
motifs due to variation. Of 563 non-glycoproteins, 524 gained one
and 39 gain 2–4 new NXS/T sites, respectively (Table S2). In the
loss set, 19 proteins lost the only existing N-glycosylation site and
an additional 5 proteins with two N-glycosylation sites had both
sites modified by nsSNV. The conversion of a protein from non- to
N- glycosylated is the most dramatic change but the changes in N-
glycosylation multiplicity cannot be disregarded in view of results
demonstrating that the total number of N-glycan branches affects
function [24].
Based on UniProtKB/Swiss-Prot annotation of the 1091
proteins, 178 proteins are annotated with the keyword ‘‘secreted’’
and 477 with keyword ‘‘membrane’’ (Table 2). Our data set also
contains many cytoplasmic and nuclear proteins which most likely
are not glycosylated [9]. However, the information on localization
of the proteins and their N-glycosylation in human population is
incomplete and in many cases dependent on the state of the cell.
For example, UniProtKB/Swiss-Prot annotates 65 out of the 204
cytoplasmic proteins with a new NXS/T (Table 2) also as either
membrane bound or secreted. Similarly, out of 218 nuclear
proteins, 36 are annotated as membrane bound or secreted at
some point of their life cycle. In addition, the location of proteins
may change in a disease context which may not be currently
captured in UniProtKB/Swiss-Prot annotation. Further analysis of
the proteins that gain glycosylation motifs by the NetNGlyc server
shows that 84% of the proteins with new NXS/T sequon are
predicted to be glycosylated using default cutoffs (data not shown).
This high percent of positive predictions indicates that the SNVs
might indeed have a functional impact, though it is possible that
some of them could be false positives (there are also false negatives;
for example SHBG is not predicted to be glycosylated by the
NetNGlyc server but is known to be glycosylated [27]). To further
check the results obtained from NetGlyc we used the neural-
network-based prediction program Predotar which is capable of
Table 3. Frequency of amino acids that are part of the glycosylation motif.
Amino acid
# in complete
proteome # in gly motif
# of nsSNV that abolishes/creates an
amino acid that is located outside of N-gly
# of nsSNV that results in loss/
gain of N-gly
N 438455 18662 4188/3990 126/553
S 991278 10268 8390/8867 54/303
T 617501 8394 7265/7258 90/243
doi:10.1371/journal.pone.0036212.t003
Figure 2. IPA results for functional analysis of the protein data set. The threshold for all the analyses was set to p,0.05 and the data is
plotted against –log of p values. The top three categories with lowest p value are presented for three IPA categories: A. molecular and cellular
functions; CTCSI -Cell to Cell Signaling and Interaction, CM- Cellular Movement, CFM- Cellular Function and Maintenance. B. physiological system
development and functions; TD- Tissue Development, OD- Organismal Development HSDF- Hematological System Development and Function. C.
canonical pathways; CS- Coagulation System, IPAP- Intrinsic Prothrombin Activation Pathway, CES- Caveolar mediated Endocytosis Signaling.
doi:10.1371/journal.pone.0036212.g002
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believed to be the site of addition of N-linked oligosaccharides).
Out of the 1091 proteins that were identified to be affected by
nsSNVs, 37% pass through the endoplasmic reticulum and 56%
were predicted to be ‘‘mitochondrial’’ or had no targeting
sequence (Table S3). We analyzed these proteins and found that,
even though they did not have ER targeting sequences, several of
them have been experimentally proven to be N-glycosylated.
Examples of such proteins include glucosylceramidase
(GLCM_HUMAN) [36,37], antithrombin III (ANT_HUMAN),
[38–40], sphingomyelin phosphodiesterase (ASM_HUMAN) [41]
and many others. Based on our evaluation of the NetNGlyc and
Predotar’s results, we conclude that the entire dataset, irrespective
of the prediction results, should be functionally analyzed to avoid
any bias that might be present in the prediction programs and
current annotation in the databases. To stimulate experimental
verification of the gain and loss of glycosylation sites, the entire
dataset with Predotar predictions are provided in Table S3.
Recent work by Park and Zhang comparing mouse, rat,
chicken, and human N-glycosylation shows that the NXS/T
motifs that contain glycosylated asparagines are more conserved
(in a panel of organisms) than the motifs that have non-
glycosylated asparagines of the same proteins [24]. This suggests
that the variations that lead to changes of the glycosylation pattern
of a protein can be damaging. To better understand if there is a
bias in terms of variations that affect the N-glycosylation motif, we
calculated the frequency of all three amino acids that are affected
by variation (Table 3). The results indicate that there is a slightly
lower percentage of variation in asparagine at the N-glycosylation
motif compared to asparagines that lie outside of the N-
glycosylation motif (this holds true for serine and threonine)
(Table 3).
Figure 3. Network of the interactions of secreted proteins. Multiplicity of lines connecting individual proteins indicates the level of evidence
for the interactions. A green line - neighborhood evidence; a blue line - concurrence evidence; a purple line - experimental evidence; a light blue line-
database evidence; a black line – co-expression evidence. Antithrombin III (SERPINC1) is boxed in red and the interacting partners are marked with
red arrows.
doi:10.1371/journal.pone.0036212.g003
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To better understand the distribution of the variants in
functional protein groups, we have analyzed our dataset to see if
there is over- or under- representation (compared to the human
proteome) of functional elements such as domains and pathways.
We find that the most significantly over-represented Pfam domains
(out of a total of 12,015 Pfam domains), both in the loss and gain
datasets, are the Immunoglobulin I-set domain (p-value 3.84E-25),
Tyrosine kinase (p-value 5.20E-24), Fibronectin type III domain
(p-value 2.90E-23), and regular and calcium-binding EGF domain
(p-value 4.06E-21). All of these domains are found in secreted
proteins and/or on the extracellular part of membrane proteins.
The domain analysis shows an over-representation of proteins that
are involved in cell-adhesion, cellular proliferation and wound
healing. This theme is repeated in all of the functional analyses
described below.
Ingenuity Pathway Analysis. Ingenuity Pathway Analysis
(IPA) was used to further explore functional aspects of our protein
dataset. We describe here the top 3 significant results (the
remaining categories are described in Table S4). A total of 134 N-
glycoproteins in our dataset are involved in cell-to-cell signaling
and interaction (CTCSI) and 122 are involved in cellular
movement (CM), the top two molecular and cellular functions
(Figure 2). CTCSI represents primarily proteins involved in
adhesion and activation of various cells of the immune system.
Specific enriched immune functions include responses of phago-
cytes, neutrophils and antigen presenting cells. The main proteins
that contribute to the immune responses were found to be
transmembrane receptors such as toll-like receptor 4 (TLR4), beta
2 microglobulin (B2M), a component of MHC class 1 molecule,
Fas (TNF receptor superfamily, member 6), IL2RA (interleukin 2
receptor alpha) and others. There are several reasons why these
proteins could be more affected by polymorphism in the N-
glycosylation sites. For example, it is known that N-linked
glycosylation of toll-like receptors is required for their translocation
to the cell surface [42]. N-linked glycosylation is known to activate
NFkappaB signaling, an important pathway in the immune
response [43].
In the cellular movement category, migration, invasion and
movement of cancerous cells are the major enriched classes. Most
of the proteins contributing to this important feature are tyrosine
kinases such as PTK2B, ERBB3, EPHB4, and FGFR1. Tyrosine
kinases play a vital role in many cellular functions such as cell
differentiation, proliferation, motility and cell survival. Mutations
in these kinases lead to deregulation of various cellular processes
resulting in unbalanced proliferation and differentiation, which
can result in cancerous growths [44]. Receptor tyrosine kinases
have been suggested as drug targets in cancer therapy but cancer
cells tend to develop resistance to these therapeutics. Targeting N-
linked glycosylation, a highly regulated step for maturation of these
receptors, is a novel therapeutic idea. A recent study pointed out
Figure 4. Effect of loss of N-linked glycosylation in cathepsin D due to nsSNV. A. Crystal structure of cathepsin D (PDB id: 1LYA) in complex
with a bound N-linked oligosaccharide. The glycosylation motif extends from a loop to a strand with the N in the loop and the remainder in the
strand. The interacting residues in pink from Chain A (134NGT136) and N209 from Chain B are shown as sticks. Oxygen atoms are colored in red and
nitrogens in blue. The oligosaccharide (NAG-NAG-BMA-MAN) forms a hydrogen bond with N134, T136 and N209. B. Crystal structure of cathepsin
D (PDB id: 1LYA) depicting the variation at position 136 from T to an A. There is a change in the charge distribution resulting in a loss of a hydrogen
bond. This may result in the loss of the glycosylation site. A and B within parenthesis represent the chain Ids within the PDB.
doi:10.1371/journal.pone.0036212.g004
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kinase signaling and radiosensitizes tumor cells [45]. The authors
also suggested that enzymatic steps regulating N-linked glycosyl-
ation can serve as novel targets in the treatment of malignancy in
general. The next top functional category predicted by IPA was
cellular function and maintenance. Most glycosylated proteins in
this category are involved in cytoskeleton organization such as
organization of actin filament extension of cellular protrusions;
transportation through ion-channels (e.g. flux of calcium ions) and
depolarization of cellular and mitochondrial membranes.
Analysis of physiological system function and development
identified over-representation of proteins involved in tissue,
organismal and, hematological system development (Figure 2).
The tissue development category comprises development of
various organs such as liver, kidney, and bone by adhesion of
cells. The organismal development refers to a broad category
comprising developmental stages from zygote to multicellular
animal or from young adult to aged adult. All the major processes
in this category are influenced by polymorphic N-glycoproteins. It
is not surprising to note such a global effect of N-linked
glycosylation because this pathway expanded significantly in
multicellular organisms especially in the vertebrates. It has been
shown that N-glycosylation influences many biological processes in
an organ and species specific manner [46]. Many of the knockout
mouse models targeting enzymes of the N- glycosylation enzymatic
pathway are embryonic lethal since they affect organ develop-
ment.
Pathway analysis by IPA identified 13 of 35 glycoproteins
involved in the coagulation system among the polymorphic
glycoproteins (p,0.05). Similarly, 11 out of 29 molecules in the
intrinsic prothrombin activation pathway matched our dataset
(p,0.05). The top two pathways, the coagulation system (extrinsic)
and the intrinsic prothrombin activation pathway, refer to the
coagulation cascade [47] where glycosylation is known to be
important [48].
Clustering analysis. To further understand protein families,
we have clustered all the proteins based on significant end-to-end
similarity. Major clusters include the G protein-coupled receptor
(GPCR) cluster (42 proteins), the kinase (EGF receptor subfamily)
cluster (27 proteins), the HLA class I histocompatibility antigen
type proteins (17 proteins) and proteases (13 proteins) (see Table
S5). This is in agreement with the results of the domain and
pathway analyses.
With 42 members (expected 38; hence not over-represented)
GPCRs form the largest cluster in our dataset. Even though the
GPCRs are not over-represented, we provide a brief description of
the cluster members as this cluster is the largest in our dataset. All
the proteins in this group are membrane proteins with 20 olfactory
receptors representing a major subset. It is known that glycosyl-
ation of GPCRs, the largest family of cell-surface receptors, is
central to normal reproduction [49,50]. Glycosylation of these
receptors also affects stability and localization of the proteins. For
example, mutation of glycosylation sites of the glucagon-like
peptide 1 receptor (GLP1R) result in aberrant distribution with
most of the receptor localized in the endoplasmic reticulum and
golgi compartments instead of the cell surface [29]. This is one of
the reasons why we include all the proteins in our analysis
irrespective of their annotated location in UniProtKB/Swiss-Prot.
The kinase (EGF receptor subfamily) cluster is over-represented
for the tyrosine kinases (expected 6, observed 21) including
receptor tyrosine-protein kinase erbB-4 (ERBB4), fibroblast
growth factor receptor 2 (FGFR2) and tyrosine-protein kinase
Tec (TEC). All of the proteins in this cluster are ATP-binding
proteins and the majority of them (21 out of 27) are known
membrane/secreted proteins. 17 of the 21 tyrosine kinases in our
list are annotated as receptors with a ligand-binding extracellular
domain and a catalytic intracellular kinase domain. Analysis of this
subset showed that 15 proteins contain a new NXS/T in the
extracellular region and are expected to be functionally affected by
N-glycosylation [24,44]. We further explored the connection of
these proteins with diseases and, as expected, several map to
cancer diseases, with the majority implicated in colorectal and
breast cancers. For example, the variat T140I in ERBB4, leads to
loss of a glycosylation motif and altered development of colorectal
adenocarcinoma [51].
HLA class I histocompatibility antigens (17 proteins) consist of
membrane/secreted proteins including HLA class I histocompat-
ibility antigen, beta-2-microglobulin, and T-cell surface glycopro-
tein CD1c. The majority of the proteins are involved in immune
responses as part of the MHC protein complex. This group of
proteins is also over-represented (expected 7, observed 17) in our
dataset. It is known that glycosylation plays an important role in
molecules of the MHC that present antigens to T cells [52] as part
of the adaptive immune response [53].
Serine proteases represent another set of proteins with over-
represented NXS/T variants (expected 7, observed 13). N-
glycosylation of the proteases and their substrates plays an
important role in protease activity. The serine proteases partici-
pate in the processes of blood coagulation, apoptosis and
inflammation [54]. All of the processes described above represent
a recurrent theme in our analysis and point out the overall
importance of N-glycosylation in these pathophysiological path-
ways. Overall the protein families that are over-represented in our
dataset based on cluster analysis show that protein involved in
immunity, blood coagulation and kinase activity are the major
types that undergo changes in glycosylation. A survey of nsSNV in
these proteins reveals that there is an abundance of nsSNVs in the
blood coagulation pathway proteins and serine proteases (number
of amino acids in the human proteome 11293923, total nsSNVs
494983; number of nsSNVs inside data set 1959, expected 1335,
p-value 0.05). The difference between the expected and observed
is less for HLA class I histocompatibility antigens and related
proteins with the MHC domain (number of nsSNVs inside data set
1952, expected 2070, p-value 0.40) and for the kinases with the
protein tyrosine kinase domain (number of nsSNVs inside data set
5670, expected 4749, p-value 0.09). It is possible that the blood
coagulation group of proteins indeed has a high level of variation
or there is a distinct bias in the research community towards these
groups of proteins. Availability of more data will allow us to
identify if there is indeed a bias in the research focus, which
subsequently results in more depositions of SNVs for some of these
functional groups.
In some rare cases, such as HLA class I histocompatibility
antigens (HLA-B and HLA-C) and tubulins (TBA1C_HUMAN
and TBA1B_HUMAN), the change that leads to gain of
glycosylation occurs in the same N-glycosylation motif in the
related proteins and could indicate a common functional effect in
the gene family. Unlike the HLA class I histocompatibility
antigens, which are membrane proteins, the tubulins are found
in the cytoplasm and cytoskeleton and therefore are not expected
to be glycosylated. There are reports on tubulin glycosylation and
it has been suggested that some portions of the a and b tubulin are
translated in the endoplasmic reticulum and hence it is possible
they might be glycosylated [55,56].
Structural analysis. We performed structural analysis to
elucidate where the modifications are located. We found that 277
out of 1091 proteins have structures available in the Protein Data
Bank (PDB) [57] at the position of variation. It was previously
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conformation [58]. Later it was found that many turns or loop
conformations are suitable to produce an exposed glycosylation
site [59]. Petrescu et al. analyzed the secondary structures at the
N-glycosylation sites and found that turns and bends are favored
with ,27% and 18% of occupied sites on turns and bends with the
lowest glycosylation site incidence (11%) on helices [60]. We
notice that the majority of the variations are within the loop and
bend regions (32% are in loop regions, 16% in bends, 10% in the
strands and 22% in the helices). Zielinska et al. predicted the
secondary structure localizations in mouse glycoproteins and
suggested that 71% of the N-linked asparagines are located in the
loop regions. [9]. A survey of the distribution of SNPs in the
different secondary structures shows that there is no bias in
the occurrence of nsSNPs in the different secondary structural
elements (number of SNPs inside loops/turns: 1385, expected
1305; strands: 9374 expected: 8355; helix: 14118, expected:
13376). These findings indicate that although the nsSNPs that
affect N-glycosylation motifs are enriched in the loop and bend
region (48%) and under-represented in the other secondary
structural elements, the enrichment is not as high as expected
based on the fact that 71% of the aspargines are located on loops.
This can be attributed to the fact that N-glycosylation sites in loops
are functionally important and hence, less likely to contain
variation.
We found that 189 proteins in our dataset are secreted based on
UniProtKB/Swiss-prot annotation and prediction results from
WoLF PSORT [61]. Network analysis followed by Gene
Ontology enrichment analysis of these 189 proteins using
STRING [62] reveals that a large number of these proteins are
involved in blood coagulation. Response to wounding, platelet
activation, blood coagulation and hemostasis belong to the top
terms, ranked based on p-value. We also saw blood coagulation
pathway as one of the top canonical pathways predicted by IPA
and over-representation of this set in our clustering and domain
analysis was also observed. Antithrombin III, a protein which loses
an NXS/T site due the N167T substitution, is found to interact
with ten proteins of which 9 are involved in blood coagulation
pathway based on STRING network analysis (Figure 3). We have
selected this protein to carry out structural and functional analysis
as described below. Availability of structure in PDB (2ANT) of
antithrombin III allowed us to model the variation and see the
effect of loss of glycosylation motif (UniProtKB accession P01008,
position 167NKS169; PDB id 2ANT, position 135NKS137). As
there is no carbohydrate attached to the glycosylation motif
167NKS169, this is an example of changes can be observed at the
structural level due the loss of the glycosylation motif. Modeling
results show that the loss of glycosylation motif does not result in
significant changes to the structure when compared with 2ANT
(0.42A ˚ RMSD). Our model also shows that the variation increases
the relative solvent accessibility (RSA) of that region from 0.69 to
1.00, which could have an effect on heparin binding (heparin
binding site: F156– G180 [63]). Bayston et al. [64] investigated the
role of loss of glycosylation on antithrombin deficiency in an
asymptomatic individual (and family) with borderline levels of
antithrombin. Direct sequencing confirmed the mutation that
leads to N167T substitution and loss of glycosylation near the
heparin interaction site which results in deficiency of total
antithrombin in the plasma of the asymptomatic individual and
her family. The author’s hypothesize that the loss of glycosylation
results in more conformational flexibility which in turn results in
lower affinity binding to heparin. Our modeling studies do not
show any conformational flexibility but it is possible that the
carbohydrate assists in heparin binding and its loss could lead to
lower binding affinity to heparin.
In the second example we chose a protein that has a
carbohydrate attached to the glycosylation motif. Based on our
functional analysis using IPA, we had observed that cathepsin D,
an acid protease, is in the list of top cellular, molecular functions
and diseases such as metabolic, genetic and developmental
disorders and has a structure available with a carbohydrate
attached at the variant glycosylation sequon. The loss of the N-
glycosylation motif is caused by the variation T136A in this
protein (UniProtKB accession P07339, position: 134NGT136;
PDB id 1LYA, position: 70NGT72). While there were no major
structural changes, we did observe a loss of a hydrogen bond that
originally existed between the threonine residue and the sugar
(Figure 4a and 4b). This also changed the charge distribution at
the site making it more neutral with the alanine present. Also,
there was an increase in solvent accessibility of the asparagine from
0.45 to 0.62 and a decrease in the accessibility at the site of the
variation from 0.53 for threonine to 0.45 for alanine. There is
evidence in the literature for the role of glycosylation in the
regulation of cathepsin D in cancers [65]. Cathepsin D contains
two N-glycosylation sites at positions 134 and 263 and both sites
are important for targeting to lysosomes [66]. While we cannot test
this with our data, it is tempting to speculate that the occurrence of
the nsSNV in one of the sites interferes with its stability and
lysosomal targeting. The example demonstrates the potential of
such analysis to stimulate laboratory verification of these
interesting functional characteristics.
To summarize, the results obtained from this study provide for
the first time, not only a comprehensive survey of the effect of
nsSNVs on the human glycoproteome, but also a framework that
will assist glycobiologists with sorting and ranking of the datasets
available in Tables S1, S2, S3, S4, and S5 to identify proteins of
interest. These candidates can be further analyzed in the
laboratory to test functional predictions. The structural analysis
of antithrombin-III and cathepsin D provides a method that can
be applied to study the functional implications of variation that
lead to change of glycosylation in other proteins. The requirement
is that these proteins either have a solved 3D structure or have
closely related proteins with solved structures. The amount of
information available on the 1091 proteins described in this paper
is vast and is constantly being updated by the UniProtKB/Swiss-
Prot curation team. A brief description is provided here to
facilitate browsing the datasets in UniProt. Copy accessions from
Tables S1, S2, S3, S4, and S5, paste them in the UniProt
identifiers input box at http://www.uniprot.org/batch and click
on retrieve; in the intermediate window click on UniProtKB to
view the results in tabular format; next, one can either browse
individual proteins by clicking on the accession numbers or browse
by Gene Ontology or UniProtKB/Swiss-Prot keywords by
clicking. Availability of more SNV data from ongoing genome
sequencing projects, validation of N-glycosylation sites, and
availability of more functional data on individual proteins will
undoubtedly unravel how variation in this important post-
translation modification affects human biology.
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